Selected reviews published before 2021.

The Dynamic Origins of Type 1 Diabetes.

Leslie RD, Grant SFA. Diabetes Care. 2018 Dec;41(12):2441-2443. doi: 10.2337/dci18-0034.PMID: 30459244.

Allostasis and the origins of adult-onset diabetes.

Leslie RD, Vartak T.Diabetologia. 2020 Feb;63(2):261-265. doi: 10.1007/s00125-019-05048-9.PMID: 31813006.

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.

Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, Leslie RD.Diabetes. 2020 Oct;69(10):2037-2047. doi: 10.2337/dbi20-0017. Epub 2020 Aug 26.PMID: 32847960.

Type 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection.

Akhbari P, Richardson SJ, Morgan NG. Microorganisms. 2020 Sep 15;8(9):1419. doi: 10.3390/microorganisms8091419.PMID: 32942706.

Reviews published in 2021 

Adult-Onset Type 1 Diabetes: Current Understanding and Challenges.

Leslie RD, Evans-Molina C, Freund-Brown J, Buzzetti R, Dabelea D, Gillespie KM, Goland R, Jones AG, Kacher M, Phillips LS, Rolandsson O, Wardian JL, Dunne JL.Diabetes Care. 2021 Nov;44(11):2449-2456. doi: 10.2337/dc21-0770.PMID: 34670785.

Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality.

Quinn LM, Wong FS, Narendran P. Front Immunol. 2021 Oct 1;12:737964. doi: 10.3389/fimmu.2021.737964. eCollection 2021.

100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.

Pearson JA, McKinney EF, Walker LSK. Immunother Adv. 2021 Nov 24;1(1):ltab024. doi: 10.1093/immadv/ltab024. eCollection 2021 Jan.

Analysis of overlapping genetic association in type 1 and type 2 diabetes.

Inshaw JRJ, Sidore C, Cucca F, Stefana MI, Crouch DJM, McCarthy MI, Mahajan A, Todd JA.Diabetologia. 2021 Jun;64(6):1342-1347. doi: 10.1007/s00125-021-05428-0. Epub 2021 Apr 8.

Diabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention.

Charles MA, Leslie RD.Diabetes. 2021 Nov;70(11):2444-2456. doi: 10.2337/dbi21-0012.PMID: 34711669.

Four decades of the Bart’s Oxford study: Improved tests to predict type 1 diabetes.

Gillespie KM, Fareed R, Mortimer GL. Diabet Med. 2021 Dec;38(12):e14717. doi: 10.1111/dme.14717. Epub 2021 Oct 26.PMID: 34655243 Review.

Presumption of guilt for T cells in type 1 diabetes: lead culprits or partners in crime depending on age of onset?

Carré A, Richardson SJ, Larger E, Mallone R. Diabetologia. 2021 Jan;64(1):15-25. doi: 10.1007/s00125-020-05298-y. Epub 2020 Oct 21.PMID: 33084970.

General population screening for childhood type 1 diabetes: is it time for a UK strategy?

Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T.Arch Dis Child. 2022 Sep;107(9):790-795. doi: 10.1136/archdischild-2021-321864. Epub 2021 Nov 5.

Insights From Single Cell RNA Sequencing Into the Immunology of Type 1 Diabetes- Cell Phenotypes and Antigen Specificity.

Hanna SJ, Tatovic D, Thayer TC, Dayan CM.Front Immunol. 2021 Oct 1;12:751701. doi: 10.3389/fimmu.2021.751701. eCollection 2021.

Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes.

Tatovic D, Dayan CM.Diabet Med. 2021 Dec;38(12):e14696. doi: 10.1111/dme.14696. Epub 2021 Sep 29.

Preventing type 1 diabetes in childhood.

Dayan CM, Besser REJ, Oram RA, Hagopian W, Vatish M, Bendor-Samuel O, Snape MD, Todd JA.Science. 2021 Jul 30;373(6554):506-510. doi: 10.1126/science.abi4742.

A little help from residual β cells has long-lasting clinical benefits.

Lam A, Dayan C, Herold KC.  J Clin Invest. 2021 Feb 1;131(3):e143683. doi: 10.1172/JCI143683.

Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides.

Singh RK, Malosse C, Davies J, Malissen B, Kochba E, Levin Y, Birchall JC, Coulman SA, Mous J, McAteer MA, Dayan CM, Henri S, Wong FS.Nanomedicine. 2021 Feb;32:102321. doi: 10.1016/j.nano.2020.102321. Epub 2020 Oct 23.

Historical and new insights into pathogenesis of type 1 diabetes (2).

Wong FS, Tree TI.Clin Exp Immunol. 2021 May;204(2):165-166. doi: 10.1111/cei.13597.

Identifying the ‘Achilles heel’ of type 1 diabetes.

Battaglia M, Buckner JH, Levings MK, Richardson SJ, Wong FS, Tree TI.Clin Exp Immunol. 2021 May;204(2):167-178. doi: 10.1111/cei.13570. Epub 2021 Feb 22.

Regulatory B Cells in Type 1 Diabetes.

Boldison J, Da Rosa LC, Wong FS.Methods Mol Biol. 2021;2270:419-435. doi: 10.1007/978-1-0716-1237-8_22.

100 YEARS OF INSULIN: Pancreas pathology in type 1 diabetes: an evolving story.

Richardson SJ, Pugliese A.J Endocrinol. 2021 Dec 9;252(2):R41-R57. doi: 10.1530/JOE-21-0358.

Widening health inequalities related to type 1 diabetes care in children and young people in the UK: A time to act now.

Ng SM, Evans ML.Diabet Med. 2021 Nov;38(11):e14620. doi: 10.1111/dme.14620. Epub 2021 Jun 26.

Preventing Cardiovascular Complications in Type 1 Diabetes: The Need for a Lifetime Approach.

Chiesa ST, Marcovecchio ML.Front Pediatr. 2021 Jun 9;9:696499. doi: 10.3389/fped.2021.696499. eCollection 2021.

Editorial: Debates in Clinical Management in Pediatric Endocrinology.

Marcovecchio ML, Predieri B, De Filippo G, Delvecchio M.Front Endocrinol (Lausanne). 2021 Mar 10;12:663860. doi: 10.3389/fendo.2021.663860. eCollection 2021.

Regulatory B Cells: Role in Type 1 Diabetes.

Boldison J, Wong FS.Front Immunol. 2021 Sep 20;12:746187. doi: 10.3389/fimmu.2021.746187. eCollection 2021.

Circadian Rhythm Modulation of Microbes During Health and Infection.

Pearson JA, Voisey AC, Boest-Bjerg K, Wong FS, Wen L.Front Microbiol. 2021 Aug 27;12:721004. doi: 10.3389/fmicb.2021.721004. eCollection 2021.

Inflammasomes and Type 1 Diabetes.

Pearson JA, Wong FS, Wen L.Front Immunol. 2021 Jun 9;12:686956. doi: 10.3389/fimmu.2021.686956. eCollection 2021.

Hyperinsulinaemic-hypoglycaemic glucose clamps in human research: a systematic review of the literature.

Fabricius TW, Verhulst CEM, Kristensen PL, Tack CJ, McCrimmon RJ, Heller S, Evans ML, Amiel SA, Pieber TR, de Galan BE, Pedersen-Bjergaard U; Hypo-RESOLVE consortium.Diabetologia. 2021 Apr;64(4):727-736. doi: 10.1007/s00125-020-05361-8. Epub 2021 Feb 10.

Reviews published in 2022 

Adult-onset autoimmune diabetes.

Buzzetti R, Maddaloni E, Gaglia J, Leslie RD, Wong FS, Boehm BO.Nat Rev Dis Primers. 2022 Sep 22;8(1):63. doi: 10.1038/s41572-022-00390-6.PMID: 36138034 Review.

Targeting TFH cells in human diseases and vaccination: rationale and practice.

Yu D, Walker LSK, Liu Z, Linterman MA, Li Z.Nat Immunol. 2022 Aug;23(8):1157-1168. doi: 10.1038/s41590-022-01253-8. Epub 2022 Jul 11.

The link between circulating follicular helper T cells and autoimmunity.

Walker LSK.Nat Rev Immunol. 2022 Sep;22(9):567-575. doi: 10.1038/s41577-022-00693-5. Epub 2022 Mar 11.

Screening children for presymptomatic type 1 diabetes.

Quinn LM, Rashid R, Narendran P, Shukla D.Br J Gen Pract. 2022 Dec 21;73(726):36-39. doi: 10.3399/bjgp23X731709. Print 2023 Jan.

 A systematic review and meta-analysis of interventions to preserve insulin-secreting β-cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose control.

Narendran P, Tomlinson C, Beese S, Sharma P, Harris I, Adriano A, Maggs F, Burrows M, Nirantharakumar K, Thomas N, Price MJ, Andrews RC, Moore DJ.Diabet Med. 2022 Jan;39(1):e14730. doi: 10.1111/dme.14730. Epub 2021 Nov 2.

Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.

Yang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA; Immunology of Diabetes Society T-Cell Cytometry Group.Eur J Immunol. 2022 Mar;52(3):372-388. doi: 10.1002/eji.202049067. Epub 2022 Jan 28.

Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other.

Scherm MG, Wyatt RC, Serr I, Anz D, Richardson SJ, Daniel C.Mol Metab. 2022 Oct;64:101565. doi: 10.1016/j.molmet.2022.101565. Epub 2022 Aug 6.

Temporal regulation of interferon signalling in human EndoC-βH1 cells.

Dhayal S, Leslie KA, Baity M, Akhbari P, Richardson SJ, Russell MA, Morgan NG.J Mol Endocrinol. 2022 May 19;69(2):299-313. doi: 10.1530/JME-21-0224.

ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents.

Besser REJ, Bell KJ, Couper JJ, Ziegler AG, Wherrett DK, Knip M, Speake C, Casteels K, Driscoll KA, Jacobsen L, Craig ME, Haller MJ.Pediatr Diabetes. 2022 Dec;23(8):1175-1187. doi: 10.1111/pedi.13410. Epub 2022 Sep 30.

Editorial: Latent Autoimmune Diabetes in Adults (LADA).

Leslie RD.Front Endocrinol (Lausanne). 2022 Aug 29;13:1002776. doi: 10.3389/fendo.2022.1002776. eCollection.

Adult-onset type 1 diabetes: A changing perspective.

Burahmah J, Zheng D, Leslie RD.Eur J Intern Med. 2022 Oct;104:7-12. doi: 10.1016/j.ejim.2022.06.003. Epub 2022 Jun 16.

Optimal Prandial Timing of Insulin Bolus in Youths with Type 1 Diabetes: A Systematic Review.

Mozzillo E, Franceschi R, Di Candia F, Ricci A, Leonardi L, Girardi M, Rosanio FM, Marcovecchio ML.J Pers Med. 2022 Dec 13;12(12):2058. doi: 10.3390/jpm12122058.

ISPAD Clinical Practice Consensus Guidelines 2022: Editorial.

Craig ME, Codner E, Mahmud FH, Marcovecchio ML, DiMeglio LA, Priyambada L, Wolfsdorf JI.Pediatr Diabetes. 2022 Dec;23(8):1157-1159. doi: 10.1111/pedi.13441.

ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes.

Deeb A, Babiker A, Sedaghat S, El Awwa A, Gupta K, Pulungan AB, Isa Umar U, Akanov Z, Kalra S, Zangen D, Al Adhami S, Karipidou M, Marcovecchio ML.Pediatr Diabetes. 2022 Dec;23(8):1512-1528. doi: 10.1111/pedi.13447.

ISPAD clinical practice consensus guidelines 2022: Management of children and adolescents with diabetes requiring surgery.

Kapellen T, Agwu JC, Martin L, Kumar S, Rachmiel M, Cody D, Nirmala SVSG, Marcovecchio ML.Pediatr Diabetes. 2022 Dec;23(8):1468-1477. doi: 10.1111/pedi.13446.

ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes.

Annan SF, Higgins LA, Jelleryd E, Hannon T, Rose S, Salis S, Baptista J, Chinchilla P, Marcovecchio ML.Pediatr Diabetes. 2022 Dec;23(8):1297-1321. doi: 10.1111/pedi.13429. Epub 2022 Dec 5.

Factors Associated With Diabetic Ketoacidosis at Onset of Type 1 Diabetes Among Pediatric Patients: A Systematic Review.

Rugg-Gunn CEM, Dixon E, Jorgensen AL, Usher-Smith JA, Marcovecchio ML, Deakin M, Hawcutt DB.JAMA Pediatr. 2022 Dec 1;176(12):1248-1259. doi: 10.1001/jamapediatrics.2022.3586.

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

Dunger DB, Bruggraber SFA, Mander AP, Marcovecchio ML, Tree T, Chmura PJ, Knip M, Schulte AM, Mathieu C; INNODIA consortium.Trials. 2022 May 18;23(1):414. doi: 10.1186/s13063-022-06259-z.

A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes.

Franceschi R, et al. Acta Diabetol. 2022. PMID: 35089443 Review.

Circadian rhythms and pancreas physiology: A review.

Chan K, Wong FS, Pearson JA.Front Endocrinol (Lausanne). 2022 Aug 10;13:920261. doi: 10.3389/fendo.2022.920261. eCollection 2022.

Innate immunity in latent autoimmune diabetes in adults.

Huang J, Pearson JA, Wong FS, Wen L, Zhou Z.Diabetes Metab Res Rev. 2022 Jan;38(1):e3480. doi: 10.1002/dmrr.3480. Epub 2021 Jun 22.

Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review.

Verhulst CEM, Fabricius TW, Teerenstra S, Kristensen PL, Tack CJ, McCrimmon RJ, Heller S, Evans ML, Amiel SA, Pedersen-Bjergaard U, de Galan BE; Hypo-RESOLVE consortium.Diabetologia. 2022 Oct;65(10):1601-1612. doi: 10.1007/s00125-022-05749-8. Epub 2022 Jul 22.

Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium.

Tatovic D, Jones AG, Evans C, Long AE, Gillespie K, Besser REJ, Leslie RD, Dayan CM; Type 1 diabetes UK Immunotherapy Consortium.Diabet Med. 2022 Jul;39(7):e14862. doi: 10.1111/dme.14862. Epub 2022 May 6.PMID: 35488476.

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.

Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group.Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054.

Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.

Anderson RL, DiMeglio LA, Mander AP, Dayan CM, Linsley PS, Herold KC, Marinac M, Ahmed ST.Diabetes Care. 2022 Oct 1;45(10):2189-2201. doi: 10.2337/dc22-0308.

Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.

Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M.Diabetes Care. 2022 Dec 1;45(12):3058-3074. doi: 10.2337/dci22-0018.

Reviews published in 2023. 

IL-2-based approaches to Treg enhancement.

Harris F, Berdugo YA, Tree T.Clin Exp Immunol. 2023 Mar 16;211(2):149-163. doi: 10.1093/cei/uxac105.PMID: 36399073.

A perspective on treating type 1 diabetes mellitus before insulin is needed.

Tatovic D, Narendran P, Dayan CM.Nat Rev Endocrinol. 2023 Jun;19(6):361-370. doi: 10.1038/s41574-023-00816-5. Epub 2023 Mar 13.

What does the licensing of teplizumab mean for diabetes care?

Quinn LM, Swaby R, Tatovic D, Narendran P, Besser REJ, Dayan CM.Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15071. Online ahead of print.

Type 1 diabetes.

Quattrin T, Mastrandrea LD, Walker LSK.Lancet. 2023 Jun 24;401(10394):2149-2162. doi: 10.1016/S0140-6736(23)00223-4. Epub 2023 Apr 5.

General population screening for paediatric type 1 diabetes-A qualitative study of UK professional stakeholders.

Quinn LM, Narendran P, Randell MJ, Bhavra K, Boardman F, Greenfield SM, Litchfield I.Diabet Med. 2023 May 7:e15131. doi: 10.1111/dme.15131. Online ahead of print.

The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.

Fyvie MJ, Gillespie KM.Front Immunol. 2023 May 15;14:1158278. doi: 10.3389/fimmu.2023.1158278. eCollection 2023.

A systematic review on the impact of commercially available hybrid closed loop systems on psychological outcomes in youths with type 1 diabetes and their parents.

Franceschi R, Mozzillo E, Di Candia F, Maines E, Leonardi L, Girardi M, Fedi L, Rosanio FM, Marcovecchio ML.Diabet Med. 2023 Apr 8:e15099. doi: 10.1111/dme.15099. Online ahead of print.

Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.

Arif S, Domingo-Vila C, Pollock E, Christakou E, Williams E, Tree TIM.Front Immunol. 2023 May 22;14:1183909. doi: 10.3389/fimmu.2023.1183909. eCollection 2023.

Developments in the design and delivery of self-management support for children and young people with diabetes: A narrative synthesis of systematic reviews.

Litchfield I, Barrett T, Hamilton-Shield JP, Moore THM, Narendran P, Redwood S, Searle A, Uday S, Wheeler J, Greenfield S.Diabet Med. 2023 Apr;40(4):e15035. doi: 10.1111/dme.15035. Epub 2023 Jan 6.